Louis de Mestier

Dr. Louis de Mestier

Beaujon Hospital, Université de Paris, France
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2023 in Journal of Neuroendocrinology
Verified
Journal Article
Open access
BKBeata Kos-Kudła
Beata Kos-Kudła
Justo CastañoJusto Castaño
Justo Castaño
TDTimm Denecke
Timm Denecke
EGEnrique Grande
Enrique Grande
Andreas KjaerAndreas Kjaer
Andreas Kjaer
NFNicola Fazio
Nicola Fazio
This ENETS guidance paper for well‐differentiated nonfunctioning pancreatic neuroendocrine tumours (NF‐Pan‐NET) has been developed by a multidisciplinary working group, and provides up‐to‐date and practical advice on the management of these tumours. Using the extensive experience of centres treating patients with NF‐Pan‐NEN, the authors of this guidance paper discuss 10 troublesome questions in everyday clinical practice. Our many years of experience in this field are still being verified in the light of the results of new clinical, which set new ways of proceeding in NEN. The treatment of NF‐Pan‐NEN still requires a decision of a multidisciplinary team of specialists in the field of neuroendocrine neoplasms.

1 February 2014 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CNCindy Neuzillet
Cindy Neuzillet
ATAnnemilaï Tijeras-Raballand
Annemilaï Tijeras-Raballand
Louis de MestierLouis de Mestier
Louis de Mestier
Jerome CrosJerome Cros
Jerome Cros
SFSandrine Faivre
Sandrine Faivre
EREric Raymond
Eric Raymond

1 December 2018 in Digestive and Liver Disease
Verified
Journal Article
Closed access
CNCindy Neuzillet
Cindy Neuzillet
SGSébastien Gaujoux
Sébastien Gaujoux
NWNicolas Williet
Nicolas Williet
JBJean-Baptiste Bachet
Jean-Baptiste Bachet
LBLucile Bauguion
Lucile Bauguion
PHPascal Hammel
Pascal Hammel

12 August 2017 in Neuroendocrinology
Verified
Journal Article
Open access
PDF file
Louis de MestierLouis de Mestier
Louis de Mestier
Jerome CrosJerome Cros
Jerome Cros
CNCindy Neuzillet
Cindy Neuzillet
OHOlivia Hentic
Olivia Hentic
AEAxel Egal
Axel Egal
PHPascal Hammel
Pascal Hammel
Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) are a heterogeneous subgroup of rare neoplasms that represent about a third of all poorly differentiated neuroendocrine carcinomas (PDNEC). MiNEN combine a neuroendocrine component, usually a PDNEC, and a non-neuroendocrine component, generally an adenocarcinoma, both accounting for at least 30% of the neoplasm. MiNEN are classified as high-, intermediate-, or low-grade malignancies depending on the metastatic potential of the tumour components. High-grade malignant component should be considered even if it represents <30% of the tumour. The prognosis of MiNEN is generally intermediate between those of the two “pure” components composing it. The aim of this comprehensive review of the literature is to suggest a standardized management of MiNEN. An increasing body of evidence suggests that PDNEC components share molecular abnormalities with their adenocarcinoma counterparts, but also display additional alterations. This advocates for a common origin, and that the presence of a PDNEC component in an adenocarcinoma could indicate a turning point in carcinogenesis.

18 December 2013 in Oncotarget
Verified
Journal Article
Open access
PDF file
CNCindy Neuzillet
Cindy Neuzillet
AGArmand de Gramont
Armand de Gramont
ATAnnemilaï Tijeras-Raballand
Annemilaï Tijeras-Raballand
Louis de MestierLouis de Mestier
Louis de Mestier
Jerome CrosJerome Cros
Jerome Cros
EREric Raymond
Eric Raymond
Advanced pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC) are non-curable diseases with a particularly poor prognosis. Over the last decade, research has increasingly focused on the microenvironment surrounding cancer cells, and its role in tumour development and progression. PDAC and HCC differ markedly regarding their pathological features: PDAC are typically stromal-predominant, desmoplastic, poorly vascularized tumours, whereas HCC are cellular and highly vascularized. Despite these very different settings, PDAC and HCC share transforming growth factor-β (TGF-β) as a common key-signalling mediator, involved in epithelial-to-mesenchymal transition, invasion, and stroma-tumour dialogue. Recently, novel drugs blocking the TGF-β pathway have entered clinical evaluation demonstrating activity in patients with advanced PDAC and HCC. TGF-β signalling is complex and mediates both pro- and anti-tumoural activities in cancer cells depending on their context, in space and time, and their microenvironment. In this review we provide a comprehensive overview of the role of the TGF-β pathway and its deregulation in PDAC and HCC development and progression at the cellular and microenvironment levels. We also summarize key preclinical and clinical data on the role of TGF-β as a target for therapeutic intervention in PDAC and HCC, and explore perspectives to optimize TGF-β inhibition therapy

25 October 2013 in Endoscopy
Verified
Journal Article
Closed access
Louis de MestierLouis de Mestier
Louis de Mestier
HBHedia Brixi
Hedia Brixi
RGRodica Gincul
Rodica Gincul
TPThierry Ponchon
Thierry Ponchon
GCGuillaume Cadiot
Guillaume Cadiot
Rectal neuroendocrine tumors (NETs) account for approximately one-third of all digestive NETs, with an increasing incidence and good overall prognosis. Although recent guidelines have been published, endoscopic techniques have expanded substantially and the most recent reports should be taken into account for clinical practice. The objectives of this report were to review the latest advances on prognosis, pre-interventional explorations, treatment – with particular focus on endoscopy – and surveillance of well-differentiated rectal NETs, excluding poorly differentiated and metastatic tumors.